In Vivo Pharmacology
At EnquBio, we specialize in guiding model selection and developing customized in vivo systems aligned with your specific research objectives. With extensive experience in preclinical pharmacology, our team delivers industry-leading quality and reproducible data across a wide range of therapeutic areas, positioning us as a trusted and agile partner for your in vivo research programs.
At EnquBio, we offer a broad portfolio of well-validated in vivo models that capture key features of human inflammatory and autoimmune conditions, including arthritis, colitis, dermatitis, lupus, etc. These models enable robust evaluation of pharmacodynamics, dose response, and early biomarkers of efficacy. With deep immunology expertise and a flexible approach, our team supports model selection and custom protocol development to align with your program goals and to accelerate your discovery and development of novel immunomodulatory therapies.
EnquBio offers a broad list of well-established syngeneic and CDX models across multiple tumor types, supporting both efficacy evaluation and mechanism-of-action studies. Syngeneic models, which preserve an intact murine immune system, are ideal for studying immune-oncology agents and tumor-immune interactions. CDX models, using human cancer cell lines, are widely used for evaluating targeted therapies and human biomarkers due to their reproducibility and clinical relevance. Our team can guide model selection or tailor study design based on your therapeutic goals, delivering reliable, high-quality in vivo data to support early-stage oncology programs.
At EnquBio, we offer robust immuno-oncology in vivo models, including PBMC- and HSC-based humanized mouse systems, as well as genetically engineered mouse models (GEMMs) to evaluate human immune responses to novel immune therapies. Our expertise includes FACS-based immune cell profiling, tumor-infiltrating lymphocyte (TIL) analysis, and studies using syngeneic, xenograft, and transgenic models tailored for immune-oncology research. With deep knowledge in tumor immunology and immune modulation, we provide high-quality data and end-to-end support to accelerate the development of immunotherapies.
IVIS-Based Imaging for Orthotopic Models and Drug Biodistribution
In vivo imaging systems (IVIS) offer powerful, non-invasive tools to track tumor growth, metastasis, and drug distribution in real time. At EnquBio, we integrate advanced IVIS technology with orthotopic tumor models to provide more physiologically relevant data on tumor behavior within the native tissue environment. This approach enhances the predictive value of preclinical studies, particularly in evaluating tumor progression, response to therapy, and metastatic potential. IVIS is also a valuable platform for biodistribution studies, allowing dynamic visualization of labeled therapeutic agents across tissues over time. Our team offers customized imaging protocols and quantification strategies to support your oncology and drug delivery research with greater precision and translational relevance.
Pharmacokinetic and Pharmacodynamic (PK/PD)
Pharmacokinetic and pharmacodynamic (PK/PD) studies are central to understanding drug behavior and therapeutic potential in vivo. At EnquBio, we offer full-spectrum PK support, including specialized expertise in advanced surgical routes of administration to meet the needs of complex drug modalities. Our PK studies are seamlessly integrated with PD and efficacy evaluations, providing a holistic view of drug action. We complement in vivo results with state-of-the-art ex vivo platforms, including FACS, MSD, qPCR, JESS automated Western blotting, and many others, to deliver deep mechanistic insights and translationally relevant data that drive informed decision-making in early-stage development.
Non-GLP Toxicology
Non-GLP toxicology studies are an essential and cost-effective approach for early safety evaluation before committing to resource-intensive GLP studies. At EnquBio, we offer flexible non-GLP toxicity assessments in mice and rats, including single- and repeat-dose studies, clinical monitoring, body weight tracking, hematology, clinical chemistry, and gross necropsy. These studies provide timely, actionable data to de-risk development candidates and refine study design for downstream studies. With a strong emphasis on understanding tolerability and early safety margins, our team delivers high-quality results that support confident early-stage decision making.
Other In Vivo Efficacy Models
EnquBio supports a broad range of in vivo efficacy models tailored to diverse therapeutic areas. Our portfolio includes well-established and custom models for metabolic diseases such as MASH (formerly NASH), obesity, type 2 diabetes, and cardiovascular disorders. We also offer validated models for fibrotic conditions, enabling robust efficacy assessment across multiple organ systems. Each study is designed with scientific precision and flexibility to meet your program’s unique needs, providing reliable, translatable data to guide preclinical development.